Video

First- and Later-line Use of Panitumumab in mCRC

For High-Definition, Click

Clinical trials have evaluated the use of the EGFR inhibitor panitumumab alone and in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC). The results of these trials have shown improvements in clinical outcomes with panitumumab, including progression-free survival and overall survival. Although the results were not always significant, these trials highlight the importance of RAS testing to inform treatment decisions, believes Heinz-Josef Lenz, MD.

In May 2014, the FDA approved panitumumab in combination with chemotherapy as a frontline treatment for patients with KRAS wild-type mCRC, based on findings from two phase III clinical trials. In conjunction with panitumumab, the FDA has also approved a companion diagnostic for the detection of the KRAS exon 2 mutation.

Panitumumab has also been evaluated in combination with chemotherapy in patients with mCRC who received prior chemotherapy. In this setting, the addition of panitumumab improved response rate and progression-free survival in patients with wild-type tumors, notes Marwan Fakih, MD.

Comparatively low response rates are observed with second-line panitumumab versus first-line treatment, notes John L. Marshall, MD. This difference in response rates may be due in part to early treatment, tumor size, and changes in the use of imaging, believes Alan P. Venook, MD. Moreover, when a patient experiences disease progression, the characteristics of the tumor after progression may be different from the characteristics of the original tumor, Venook states. To address this, a rebiopsy may need to be performed following progression.

Related Videos
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the sensitivity and specificity of Rapid Lung NGS for biomarker testing in NSCLC.